جست‌وجوی استاد و پژوهشگر

Mitesh J. Boradمشاهده پروفایل

استاد

• Oncology
• Cholangiocarcinoma
• Pancreatic Cancer
• +۱۲ مورد دیگر

Mitesh J. Borad, M.D., is a Professor of Medicine at Mayo Clinic in Phoenix, Arizona, with joint appointments in the Division of Hematology/Oncology and the Department of Molecular Medicine. He is a leading physician-scientist in the field of gastrointestinal oncology, particularly known for his expertise in cholangiocarcinoma, pancreatic cancer, and hepatocellular carcinoma. Dr. Borad leads the Novel Therapeutics and Therapeutic Modalities Program at the Mayo Clinic Comprehensive Cancer Center and previously directed the Gene and Virus Therapy Program and the Precision Cancer Therapeutics Program at the Center for Individualized Medicine. Getz Family Research Professor of Mayo Clinic Arizona, 2024 Leader, Novel Therapeutics and Therapeutic Modalities Program, Mayo Clinic Comprehensive Cancer Center, 2024–present Arizona Investigator of the Year, 2024 Chair, International Cholangiocarcinoma Research Network (ICRN), 2020–present Member, Hepatobiliary Cancers Panel, National Comprehensive Cancer Network (NCCN) Dr. Borad’s research is centered on developing innovative cancer therapies through genomic medicine, gene therapy, and oncolytic virotherapy. His lab has engineered novel vesiculovirus vectors devoid of neurotoxicity and hepatotoxicity, enabling repeat dosing and harnessing preexisting immunity for enhanced therapeutic effect. He focuses on epigenomic dependencies in cholangiocarcinoma, superenhancer biology, and computational discovery of biomarkers from multi-omic datasets, aiming for individualized N=1 therapies. His clinical work emphasizes first-in-human trials, having led over 50 such studies. The 15 most recent articles highlight his leadership in translational oncology, spanning from ctDNA-based minimal residual disease detection in colorectal cancer to novel PROTAC degraders targeting MET, and first-in-human virotherapy trials. His work bridges structural biology (ChAdOx1 vaccine vector) to health disparities (GWAS in Latino populations), reflecting a broad yet focused research vision. Mark R. Clements Award for Vision, Innovation and Collaboration, Cholangiocarcinoma Foundation, 2022 NIH New Innovator Award, 2014 Paul Calabresi K12 Award Arizona Investigator of the Year, 2024 Dr. Borad is a dedicated mentor to numerous trainees, many from underrepresented backgrounds, who have gone on to careers in academia, government, and industry. He has secured continuous funding from the NIH, FDA, DoD, and NCI, including multiple R01 and SPORE grants. He leads major collaborative initiatives such as the International Cholangiocarcinoma Research Network and serves on national guideline panels and review committees for the FDA, NIH, and ASCO. His laboratory operates at the intersection of virology, genomics, and immunology, driving next-generation cancer therapeutics. Dr. Borad’s team includes core researchers in molecular oncology, virology, and bioinformatics, and collaborates extensively with the Translational Genomics Research Institute (TGen). His lab is part of the Mayo Clinic’s Center for Individualized Medicine and the Comprehensive Cancer Center, with access to state-of-the-art core facilities for genomics, imaging, and clinical trial support.

Martha K. Terrisمشاهده پروفایل

استاد

• Prostate Cancer
• Bladder Cancer
• Kidney Cancer
• +۵ مورد دیگر

Martha K. Terris, MD, FACS, serves as Professor and Chair of the Department of Urology at the Medical College of Georgia, Augusta University, holding the Witherington Distinguished Chair in Urology. She concurrently serves as Co-Director of the Cancer Center and maintains appointments in The Graduate School and College of Allied Health Sciences (Physician Assistant Program). Education: BS in Biology, Mississippi State University (1982) MD, University of Mississippi (1986) General Surgery Residency, Duke University Urologic Surgery and Oncology Fellowship, Stanford University Research Focus: Dr. Terris specializes in prostate, bladder, and kidney cancers with emphasis on racial disparities, cardiovascular comorbidities in prostate cancer patients, molecular mechanisms of tumor progression, and urologic education. Her work leverages the SEARCH database for large-scale outcomes research in equal-access healthcare systems. Scholarly Trends: Recent publications (2022-2025) demonstrate sustained focus on prostate cancer active surveillance pathways, metastatic castration-sensitive disease management, and molecular drivers of racial disparities in bladder/renal cancers. Her SEARCH database analyses consistently address socioeconomic determinants of cancer outcomes and cardiovascular complications in prostate cancer cohorts. Scientific Awards: American Urological Association Distinguished Service Award (2022) Urology Practice Best Reviewer (2023, 2024) Urology Practice Top Reviewer (2025) Castle Connolly Top Doctors (2025) Best Doctors in America Top Doctors in Cancer Leadership and Mentoring: As Urology Residency Program Director since 2003, Dr. Terris expanded the program from one to three residents annually, with graduates pursuing fellowships and academic careers. She mentors undergraduate students and serves nationally on the ACGME Urology Residency Review Committee, American Board of Urology, and as President of the Society of Urology Chairs and Program Directors. Her leadership transformed the Division of Urology into a full Department in 2023. Research Infrastructure: Dr. Terris co-founded the SEARCH database consortium and co-directs the Cancer Center, enabling multi-institutional research on urologic cancers across Veterans Affairs and equal-access healthcare systems.

Leila Dorlingمشاهده پروفایل

پژوهشگر

• Breast Cancer Genetic Epidemiology
• Radiogenomics
• Genetic Susceptibility to Cancer
• +۳ مورد دیگر

Leila Dorling is a researcher in the Department of Public Health and Primary Care at the University of Cambridge, specializing in breast cancer genetic epidemiology. She works within the Centre for Cancer Genetic Epidemiology and has been a key contributor to the Breast Cancer Association Consortium and the Radiogenomics Consortium. Her research focuses on refining breast cancer risk estimates through pedigree analysis and investigating genetic variants associated with treatment toxicity. Research Highlights: Quantifying risks of protein truncating and missense variants in breast cancer genes Developing and validating risk prediction models like CanRisk Analyzing radiation and chemotherapy-induced toxicity through GWAS Investigating hereditary cancer syndromes and global genetic associations Teaching & Collaboration: Supervises students and teaches on the MPhil in Population Health Sciences. Active in international collaborations including BRIDGES project and 113,000+ woman breast cancer risk study.

Phuoc T. Tranمشاهده پروفایل

استاد

• Radiation Oncology
• Prostate Cancer
• Oligometastasis
• +۷ مورد دیگر

Phuoc T. Tran, MD, PhD is a Professor and Senior Vice Chair for Research in the Radiation Oncology Department at the University of Maryland School of Medicine. He specializes in treating genitourinary cancers using advanced stereotactic radiation techniques (SRS/SBRT/SABR) and focuses on improving clinical radiotherapy for prostate , adrenal , bladder , penile , testicular , and urethral cancers , particularly in oligometastatic disease contexts. Trained at Oregon Health & Sciences University (MD/PhD, 2003) and Stanford University (Residency, 2008) Board-certified in Radiation Oncology by the American Board of Radiology His research explores epithelial-mesenchymal transitions (EMT/MET) in tumorigenesis, treatment resistance, and radiation-induced fibrosis using inducible transgenic mouse models . He also investigates tumor-selective radiosensitizers to enhance radiotherapy's therapeutic ratio. Key article trends include: 2023 Eur Urol study on advanced molecular imaging for oligometastatic prostate cancer 2022 J Clin Oncol analysis of genetic predictors for metastasis-directed therapy 2021 JAMA Oncol validation of genomic classifiers in recurrent prostate cancer Scientific awards span NCI grants (1R01CA166348-01A1, 1U01CA231776-01, etc.), Movember Foundation-PCF Challenge Awards , and recognition as a Top Doctor by Baltimore Magazine (2012). He serves as a senior editor for Cancer Research and leads the Tran Laboratory , which bridges radiogenomics and radiation oncology to develop clinical innovations.

• Bronchiolitis
• Primary Ciliary Dyskinesia
• Non-CF Bronchiectasis
• +۶ مورد دیگر

Fabio Midulla is a Full Professor in Pediatrics at the Department of Maternal and Child Health and Urological Sciences , Sapienza University of Rome. His career spans over four decades with clinical, research, and teaching roles in pediatric pulmonology and respiratory diseases. Born: Rome, December 15, 1955 Education: MD (1980, Sapienza), PhD in Lung Physiology (1988) Clinical Roles: Director of Pediatric Emergency First Aid, Cystic Fibrosis Center attending physician Research Focus: His work centers on respiratory syncytial virus (RSV) bronchiolitis , primary ciliary dyskinesia , non-CF bronchiectasis , and bronchial asthma . He explores viral interactions, interferon responses, and long-term respiratory sequelae. Key projects include "Bronchiolitis in infants: viral, microbiological and immunological determinants" and international collaborations on pediatric bronchoscopy guidelines. Scientific Contributions: With over 20 major publications since 2015, his recent work examines SARS-CoV-2 impacts on pediatric populations, RSV variant severity, and interferon gene expression patterns. He has coordinated European studies on broncho-alveolar lavage and flexible bronchoscopy techniques. Scientific Awards: Multiple early-career scholarships from Italian National Institute of Social Welfare; Foundation 'Eleonora Lorillard Spencer Cenci' research grants Teaching & Leadership: Professor of Pediatric Pulmonology (1999-present), coordinator of European Respiratory Society bronchoscopy courses, and contributor to clinical practice guidelines. His clinical activities include managing pediatric emergencies and interventional bronchoscopy services.

Eva Furrowمشاهده پروفایل

دانشیار

• Veterinary Internal Medicine
• Canine Urolithiasis
• Hypertriglyceridemia
• +۴ مورد دیگر

Eva Furrow, VMD, PhD, Diplomate ACVIM, is an Associate Professor in the Department of Veterinary Clinical Sciences at the University of Minnesota . She holds a PhD in Comparative and Molecular Biosciences (2014) from the University of Minnesota, a VMD from the University of Pennsylvania (2007), and a BA from Harvard University (2003). Her clinical certification as a Diplomate in the American College of Veterinary Internal Medicine (2011) underscores her expertise in small animal internal medicine. PhD, University of Minnesota, 2014 VMD, University of Pennsylvania, 2007 BA, Harvard University, 2003 Diplomate ACVIM, Small Animal Internal Medicine, 2011 Dr. Furrow's research focuses on genetic and metabolic underpinnings of canine diseases , particularly calcium oxalate urolithiasis, hypertriglyceridemia, and immunodeficiencies. Her work bridges comparative medicine and molecular biology , utilizing genomic approaches to understand disease mechanisms in dogs with translational implications for human medicine. Recent publications highlight her expertise in genetic variant analysis and microbiome studies . Collaborative work on CARD9 mutations in miniature Schnauzers and CARMIL2 immunodeficiency in Cavaliers demonstrates her leadership in identifying breed-specific genetic disorders. Her studies on urine microbiome dynamics and lipoprotein subtypes reflect innovative approaches to disease classification. Dr. Furrow actively contributes to veterinary clinical research through affiliations with the University of Minnesota's Veterinary Clinical Sciences and Comparative and Molecular Biosciences programs. Her work often involves interdisciplinary collaborations with geneticists, microbiologists, and veterinary specialists.

Manish Aghiمشاهده پروفایل

استاد

• Neurosurgery
• Brain Tumor Research
• Glioblastoma
• +۷ مورد دیگر

Dr. Manish Aghi is a Professor of Neurological Surgery at the University of California, San Francisco (UCSF) and a neurosurgeon specializing in brain tumors at UCSF Medical Center. He serves as principal investigator at the UCSF Brain Tumor Research Center and is affiliated with the UCSF Weill Institute for Neurosciences. His clinical practice focuses on surgical management of brain and skull base tumors, including gliomas, meningiomas, and pituitary adenomas, with special expertise in intraoperative brain mapping for glioma surgery, pituitary tumor surgery, and minimally invasive endoscopic skull base surgery. Dr. Aghi earned his medical degree and doctoral degree in neurosciences from Harvard Medical School through the MSTP program. He completed his neurosurgery residency and postdoctoral training at Massachusetts General Hospital. He is board-certified by the American Board of Neurological Surgery. His research program investigates tumor-microenvironment interactions that drive aggressive biology and therapeutic resistance in brain tumors. His laboratory work encompasses glioblastoma angiogenesis, mechanisms of resistance to anti-angiogenic therapy, tumor-associated macrophages, whole genome sequencing of pituitary adenomas, metabolic adaptations following therapy, and tyrosine kinase-integrin receptor complexes in driving invasive resistance. His research integrates genomic, proteomic, and cellular approaches to identify novel therapeutic targets, with a clear trajectory toward developing more personalized treatment approaches for brain tumor patients. Preuss Award from the American Association of Neurological Surgeons Mahaley Award from the American Association of Neurological Surgeons Ronald L. Bittner Award from the Congress of Neurological Surgeons Synthes Skull Base Award from the Congress of Neurological Surgeons Integra Foundation Award from the Congress of Neurological Surgeons As principal investigator, Dr. Aghi has secured significant NIH funding (R01CA227136, R01NS079697, K02NS064167) focused on glioblastoma invasion, tumor microenvironment interactions, and therapeutic resistance mechanisms. He serves as PI on multiple industry-sponsored and investigator-initiated phase I-II clinical trials comparing immunotherapy versus anti-angiogenic therapy for recurrent glioblastoma, as well as investigating convection-enhanced delivery of oncolytic viruses and nanoliposomal chemotherapy. His laboratory employs advanced biomaterials systems, CRISPR screening, and multi-omic approaches to study brain tumor biology and develop novel therapeutic strategies.

• Chronic Pain Management
• Clinical Psychology
• Occupational Health
• +۳ مورد دیگر

Professor Michael Nicholas is a Clinical Psychologist with over 40 years of experience in chronic pain research and management. He holds a conjoint Professor position at the Pain Management Research Institute within the Northern Clinical School, University of Sydney , and directs multidisciplinary pain management programs at the MJC Pain Management & Research Centre , Royal North Shore Hospital. He established the first Multidisciplinary Back Pain Program at Westmead Hospital (1988) and developed the globally used Pain Self-Efficacy Questionnaire (PSEQ) . With a PhD from the University of Otago (1988) and an MSc(Hons), he has held leadership roles at St Thomas's Hospital (London), University of NSW (1991), and since 1994 at University of Sydney. PhD, University of Otago MPsychol (Clin) MSc(Hons), University of Sydney His research focuses on psychosocial contributors to chronic pain , early intervention protocols, and workplace disability prevention. He co-developed the Örebro Musculoskeletal Pain Screening Questionnaire with Sweden's Steve Linton, influencing WHO's ICD-11 pain classification. His work on the WISE study (2013–2022) demonstrated cost-effective interventions for injured workers, adopted by NSW Health. Recent publications (2020–2024) emphasize telehealth pain care , cross-cultural pain assessment tools , and workplace pain management . His 15 most recent articles address low back pain interventions, predictive modeling, and economic analyses of multidisciplinary programs. IASP John D Loeser Lifetime Achievement Prize (2022) Honorary Doctorate, Örebro University (2015) Australia's Research Field Leader for Pain (2020–2023) NSW Agency for Clinical Innovation Pain Network Co-Chair (2016–2022) He has trained over 400 ADAPT Pain Management Programs since 1994 and leads the internationally recognized online Masters Degree in Pain Management at University of Sydney. His work extends to opioid deprescribing , rehabilitation psychology , and low-resource setting adaptations . As Associate Editor for PAIN , Journal of Occupational Rehabilitation , and Scandinavian Journal of Pain , he shapes global pain scholarship. His grants exceed $12 million, including $4 million in recent years for rural pain training and CALD community programs.

• Breast Cancer Radiotherapy
• Gynecologic Oncology
• Radiation Therapy Techniques
• +۳ مورد دیگر

Susan A. Higgins is a Professor of Therapeutic Radiology and Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine. She serves as Vice Chair for Wellness and Engagement in Therapeutic Radiology and Medical Director for Radiation Oncology at Shoreline Medical Center, Yale New Haven Hospital. Her research focuses on breast cancer radiotherapy, gynecologic oncology, and radiation therapy techniques. MD from University of Rochester (1990) Intern at St. Mary’s Hospital, University of Rochester (1991) Residency in Therapeutic Radiology at Yale University (1992) Dr. Higgins specializes in breast cancer radiotherapy, emphasizing tailored radiation regimens to maximize tumor targeting while minimizing organ exposure. Her work includes deep inspiration breath hold technique, stereotactic radiation for metastases, and clinical trials for rectal and endometrial cancers. She has contributed to radiation oncology education through multi-institutional curriculum development. Her research trends span clinical trials (YIV-906 + chemo-radiation for rectal cancer), gynecologic cancer treatment (endometrial and uterine serous carcinoma), and breast cancer recurrence analysis. She investigates predictors of vaginal stenosis post-brachytherapy and adjuvant therapies for advanced endometrial cancers. Scientific contributions include: 2024 ‘Top Doctors’ recognition 2023 ‘Top Doctors’ recognition Dr. Higgins' clinical practice is based at Shoreline Medical Center, Guilford, CT, and Yale Therapeutic Radiology. She is part of the Smilow Cancer Center and Breast Cancer Radiotherapy program at Yale.

• Oral Cancer
• Cancer Screening
• Malignant Transformation
• +۴ مورد دیگر

Denise Laronde serves as a Professor in the Department of Oral Biological & Medical Sciences at the University of British Columbia's Faculty of Dentistry, with significant affiliations to the BC Cancer Research Institute. She actively supervises graduate students in Craniofacial Science (MSc and PhD programs) and focuses on advancing oral cancer prevention through rigorous translational research. Her research program centers on oral cancer screening methodologies, early detection biomarkers, and malignant transformation mechanisms in oral premalignant lesions. Key methodologies include longitudinal dysplasia progression studies, molecular biomarker analysis (particularly E-cadherin and beta-catenin pathways), and community-based screening initiatives targeting high-risk populations. She also investigates systemic healthcare barriers, notably among dental hygiene professionals. Analysis of her recent publications reveals three dominant research thrusts: (1) Development of risk stratification models for oral cancer screening programs, (2) Molecular characterization of dysplasia progression through biomarker and microbiome analysis, and (3) Implementation science addressing real-world barriers in oral cancer prevention across diverse settings from rural India to Canadian dental practices. This work consistently bridges laboratory discovery with community application. Dr. Laronde maintains active collaborations through the BC Cancer Research Institute, emphasizing multidisciplinary approaches to oral cancer prevention. Her recent work on HPV vaccination perceptions among dentists and microbiome-based progression predictors demonstrates ongoing innovation in translating research into clinical practice.

• Internal Medicine
• Respiratory Critical Care
• Sleep Medicine
• +۳ مورد دیگر

Peter J. Edmonds is a Clinical Assistant Professor in the Department of Internal Medicine at the Spencer Fox Eccles School of Medicine, University of Utah . He specializes in Respiratory Critical Care and Sleep Medicine , with a focus on systematic reviews and meta-analyses. His clinical locations include the Huntsman Cancer Institute , University of Utah Hospital , and Sleep Wake Center . Board Certifications : American Board of Internal Medicine (Internal Medicine, Critical Care Medicine, Pulmonary Disease) Education : Undergraduate in Biology (Liberty University), MD (SUNY Upstate Medical University), Residency and Fellowship at Vanderbilt University Medical Center His research explores the intersections of internal medicine , critical care , sleep disorders , and nephrology . Recent work includes analyzing vaping-induced lung damage , sleep apnea predictors , and renal complications from medications. Patients consistently praise his attentive care and professionalism , with a 4.9/5 rating from 49 reviews.

Philip A. Suteraمشاهده پروفایل

استادیار

• Radiation Oncology
• Prostate Cancer
• Bladder Cancer
• +۷ مورد دیگر

Philip A. Sutera, M.D., is an Assistant Professor in the Department of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. He practices at the Wilmot Cancer Institute and is affiliated with the University of Rochester Medical Faculty Group (URMFG) and Accountable Health Partners (AHP). His clinical and research focus spans advanced radiation therapies for prostate and bladder cancer, with particular emphasis on oligometastatic disease and genomic biomarkers. MD, University of Pittsburgh School of Medicine (2019) Residency, Radiation Oncology, Johns Hopkins University School of Medicine (2020-2024) Internship, Internal Medicine, Allegheny General Hospital (2019-2020) Dr. Sutera's research integrates machine learning, radiomics, and genomic profiling to optimize radiation therapy outcomes. His work has been published in leading journals like Radiotherapy and Oncology and Clinical Cancer Research , with a focus on PSMA PET imaging, metastasis-free survival prediction, and pathway-based biomarkers in castration-sensitive prostate cancer. His recent publications highlight trends in artificial intelligence applications for prognostic modeling, genomic determinants of therapy response, and comparative analyses of imaging modalities (PSMA PET/CT vs conventional imaging) in oligometastatic disease. Recurring themes include stereotactic ablative radiotherapy (SABR), immune cell infiltration in chemoradiation, and mitochondrial dysfunction in radiation-induced apoptosis. ASTRO Annual Meeting Abstract Award (2024) ASCO Conquer Cancer Merit Award (2024) American Radium Society Travel Grant (2023) Bert and Sally O'Malley Award (2019) ... Dr. Sutera's clinical work involves stereotactic body radiation therapy (SBRT) for pancreatic carcinoma and salvage radiosurgery for recurrent gliomas. His research extends to DNA damage mechanisms in radiation therapy and proteomic responses to novel agents like Dinaciclib and YM155. He collaborates with teams in the STOMP and ORIOLE trials and contributes to evolving definitions of disease burden in metastatic castration-sensitive prostate cancer.

• Breast Cancer
• Surgical Oncology
• Neoadjuvant Chemotherapy
• +۱ مورد دیگر

Dr. Stephen F. Sener serves as a Part-Time Clinical Professor of Surgery at the University of Southern California, specializing in breast cancer research and surgical oncology. His work focuses on optimizing neoadjuvant chemotherapy protocols, axillary staging techniques, and treatment outcomes in safety-net medical settings. Research interests include breast cancer recurrence patterns, diagnostic imaging advancements, and healthcare disparities in oncology. His publications emphasize evidence-based surgical techniques, multidisciplinary cancer care, and improving long-term patient outcomes through innovative clinical approaches. Recent work analyzes trends in breast cancer management, including MRI-guided surgical planning, implant-associated pathologies, and infection prevention protocols. Collaborative studies with international oncology societies contribute to global knowledge exchange in surgical best practices.

• Primary Biliary Cirrhosis
• Liver Transplantation
• Hepatocellular Carcinoma
• +۵ مورد دیگر

Maria van Hooff is a Researcher in the Department of Gastroenterology & Hepatology at Erasmus University Medical Center in Rotterdam, Netherlands. Her work primarily focuses on primary biliary cholangitis, liver transplantation, and hepatocellular carcinoma with significant contributions to understanding disease epidemiology and treatment outcomes. Her research interests span several key areas in hepatology: Primary Biliary Cirrhosis and its nationwide epidemiology Liver transplantation outcomes and immunosuppression protocols Hepatocellular carcinoma recurrence prediction using novel biomarkers Advanced treatments beyond ursodeoxycholic acid for cholestatic liver diseases Prognostic scoring systems like GLOBE for disease progression Quality of life metrics in chronic liver disease management Dr. van Hooff's recent publications demonstrate a strong emphasis on collaborative research, including nationwide cohort studies in the Netherlands and analyses using the European Liver Transplant Registry. Her 2024 review article on PBC treatment approaches has garnered significant attention with 12 citations, highlighting her influence in developing therapeutic guidelines. Her work on PIVKA-II as a predictor for hepatocellular carcinoma recurrence represents innovative approaches to post-transplant monitoring, particularly in challenging low alpha-fetoprotein cases. Her scientific contributions are regularly featured in high-impact journals including JHEP Reports, European Journal of Internal Medicine, and Cancers, with multiple publications receiving substantial attention on academic platforms and social media.

• Nuclear Medicine
• Molecular Imaging
• Prostate Cancer
• +۳ مورد دیگر

Johannes Czernin is a Professor and Vice Chair in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), with a secondary appointment in the Department of Medicine. He is a leading expert in nuclear medicine and molecular imaging, particularly focusing on prostate cancer diagnostics and therapeutics. Professor, Department of Molecular and Medical Pharmacology, UCLA Vice Chair, Department of Molecular and Medical Pharmacology, UCLA Professor, Department of Medicine, UCLA His research centers on nuclear medicine , PSMA PET imaging , and radioligand therapy for prostate cancer. He has authored numerous high-impact studies on imaging biomarkers, therapeutic response evaluation, and healthcare policy in nuclear medicine. Johannes' recent publications emphasize PSMA PET/CT applications across clinical scenarios, theranostic frameworks , and imaging-guided treatment decisions . His work also addresses radiopharmaceutical economics , dosimetry , and international practice patterns in prostate cancer management. He actively contributes to clinical trial design (e.g., PSMA-SRT, VISION), professional leadership (SNMMI, EANM), and training programs for graduate and postdoctoral researchers. His collaborations span UCLA , University of Tübingen , and institutions in Europe, Australia, and Japan.